Solarwinds (SWI) was downgraded at Needham to hold from buy. Company missed expectations and has several moving parts with the MSP acquisition, Needham said.
Vantiv (VNTV) was upgraded at UBS to buy and given a $30 price target. Strong visibility and an attractive valuation, said UBS.
Vantiv (VNTV) was downgraded at Wells Fargo to market perform from outperform. Valuation call, as the company is seeing lower sales, Wells Fargo said.Vertex Pharmaceuticals (VRTX) was downgraded at UBS to neutral and given a $83 price target. Safety concerns about VX-135, UBS said. VCA Antech (WOOF) upgraded at Piper Jaffray to overweight from neutral. Price target was increased to $32. Favorable industry trends, improving margins, and upcoming buyback programs drive the bull case, Piper Jaffray said. Zynga (ZNGA) was downgraded at Needham to hold from buy. Now expected to generate negative cash flow, Needham said.
Stock Comments / EPS ChangesArch Capital Group (ACGL) numbers were raised at UBS. Estimates were raised to reflect the second-quarter earnings beat and the expectation of higher loss reserve releases, said UBS. Price target goes to $56. Biogen Idec (BIIB) numbers were increased at BMO Capital. Estimates were boosted through 2014. Company continues to execute well with Tecfidera, BMO Capital said. Market Perform rating and new $237 price target. BioMarin (BMRN) estimates were raised at UBS. Reflect the earnings beat, said UBS. Price target is $67. Bristol-Myers (BMY) estimates were cut at UBS. Estimates were reduced given the voluntary OTC recalls and investments in the Eliquis launch, said UBS. Price target is $48. Borg Warner (BWA) numbers were raised at Citigroup. Estimates were increased given margin expansion and potential for cash deployment, said Citigroup. Price target goes to $106. Cameron International (CAM) estimates were cut at UBS. Estimates were reduced given integration delays with OneSubsea, said UBS. Price target is $75. Chubb Corp. (CB) estimates were raised at UBS. Reflect the second-quarter beat and a decrease in the combined ratio outlook, said UBS. Price target is $96.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts